​

Alumis (ALMS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Alumis Revenue Highlights

0

Latest Revenue (Q)

$17.39M

Alumis Revenue by Period

Alumis Revenue by Year

DateRevenueChange
2023-12-31-100.00%
2022-12-31--

Alumis generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Alumis Revenue by Quarter

DateRevenueChange
2025-03-31$17.39M100.00%
2024-12-31-100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31-100.00%
2023-12-31-100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31--

Alumis generated $17.39M in revenue during Q1 2025, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Alumis Revenue Breakdown

Alumis Revenue Breakdown by Product

Quarterly Revenue by Product

Product/ServiceJun 25
Collaboration Revenue$2.67M
License$17.39M

Alumis's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: License (86.71%), and Collaboration Revenue (13.29%).

Alumis Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RIGLRigel Pharmaceuticals$179.28M$101.69M
GLUEMonte Rosa Therapeutics$75.62M$84.93M
ADCTADC Therapeutics$69.28M$17.40M
TNXPTonix Pharmaceuticals$10.09M$2.43M
SABSSAB Biotherapeutics$2.24M-
ALMSAlumis-$17.39M
RAPTRAPT Therapeutics--
HUMAHumacyte-$301.00K

ALMS Revenue FAQ

What is Alumis’s yearly revenue?

Alumis's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 0% compared to 2021.

What is Alumis’s quarterly revenue?

Alumis's quarterly revenue for Q1 2025 was $17.39M, a 100.00% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $0, a 100.00% increase from the previous quarter (Q3 2024), and a 0% increase year-over-year (Q4 2023). ALMS's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023).